Investor Relations
Latest Financial Results
Q2 2019
Quarter Ended Mar 31, 2019
Stock Information
Company Overview
Citius Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of important new drug products for growing markets. Citius is currently advancing three proprietary product candidates: Mino-Lok®, CITI-002 (halobetasol-lidocaine formulation) and CITI-101 (Mino-Wrap). Citius believes the markets for its products are large and underserved by the current standard of care.
Investor Contact Information
Company
Citius Pharmaceuticals, Inc.
11 Commerce Drive
First Floor
Cranford, NJ 07016
T: 908-967-6677
info@citiuspharma.com
Investor Relations
Andrew Scott
VP of Investor Relations
T: 908-967-6677 ext. 105
Transfer Agent
VStock Transfer LLC
18 Lafayette Place
Woodmere, NY 11598
T: 212-828-8436
www.vstocktransfer.com
